Home Coronavirus Expert Calls for CDC to End the COVID Vaccine Program

Expert Calls for CDC to End the COVID Vaccine Program

by Paul Ebeling

#CDC #vaccine #COVID

$PFE $MRNA

A prominent toxicologist and molecular biologist who works with MS Anderson Cancer Center-Houston says the current COVID-19 campaign is a “massive clinical trial” using the general population as subjects, and is calling for the end of the COVID vaccine program.

Janci Chunn Lindsay has “extensive experience in analyzing the molecular profile of pharmacologic responses,” according to investigative journalist Jennifer Margulis.

Ms. Lindsay was cut off by moderators at the CDC’s meeting of the Advisory Committee on Immunization Practices, but she did get a chance to say that the Pfizer’s (NYSE:PFE) and Moderna’s (NASDAQ:MRNA) gene therapy vaccines have safety concerns on several fronts.

She also pointed out that “there is a credible reason to believe that the Covid vaccines will cross-react with the syncytin and reproductive proteins in sperm, ova, and placenta, leading to impaired fertility and impaired reproductive and gestational outcomes,” and that there are enough pregnancy losses reported so far to warrant stopping the vaccines.

Ms. Lindsay was contacted after the meeting to see what additional information she had that she was not allowed to present.

In a written response, Ms. Lindsay said “there is strong evidence for immune escape and that inoculation under pandemic pressure with these leaky vaccines is driving the creation of more lethal mutants that are both newly infecting a younger age demographic, and causing more Covid-related deaths across the population than would have occurred without intervention. That is, there is evidence that the vaccines are making the pandemic worse.

Eat healthy, Be healthy, Live lively

You may also like

logo-white

Your Trusted Source for Capital Markets & Related News

© 2023 LiveTradingNews.com – For The Traders, By The Traders – All Right Reserved.

The information contained on this website shall not be construed as (i) an offer to purchase or sell, or the solicitation of an offer to purchase or sell, any securities or services, (ii) investment, legal, business or tax advice or an offer to provide such advice, or (iii) a basis for making any investment decision. An offering may only be made upon a qualified investor’s receipt not via this website of formal materials from the Knightsbridge an offering memorandum and subscription documentation (“offering materials”). In the case of any inconsistency between the information on this website and any such offering materials, the offering materials shall control. Securities shall not be offered or sold in any jurisdiction in which such offer or sale would be unlawful unless the requirements of the applicable laws of such jurisdiction have been satisfied. Any decision to invest in securities must be based solely upon the information set forth in the applicable offering materials, which should be read carefully by qualified investors prior to investing. An investment with Knightsbridge is not suitable or desirable for all investors; investors may lose all or a portion of the capital invested. Investors may be required to bear the financial risks of an investment for an indefinite period of time. Qualified investors are urged to consult with their own legal, financial and tax advisors before making any investment. Knightsbridge is a private investment firm that offers investment services to Qualified Investors, Members and Institutions ONLY. Qualified Investors are defined as individuals who have met those Qualifications in the relevant jurisdictions. Members are defined as individuals who have been accepted into the Knightsbridge membership program. Institutions are defined as entities such as banks, pension funds, and hedge funds. If you are not a Qualified Investor, Member or Institution, you are not eligible to invest with Knightsbridge. All investments involve risk, and there is no guarantee of profit. You may lose some or all of your investment. Past performance is not indicative of future results. Knightsbridge is not a registered investment advisor, and this disclaimer should not be construed as investment advice. Please consult with a qualified financial advisor before making any investment decisions. By accessing this website, you agree to the terms of this disclaimer. Thank you for your interest in Knightsbridge.